Cantor Fitzgerald Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $7

Benzinga Newsdesk www.benzinga.com Neutral 68.9%

Neg 0% Neu 68.9% Pos 0%

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $7.